Article in American journal of physiology. Gastrointestinal and liver physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Kale S BongersDivision of Pulmonary, Critical Care, and Occupational Medicine, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.ORCID 0000-0002-9297-9185
Thomas L FlottDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0002-3962-6014
Larisa YeomansDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0003-1522-1482
Lilian MaynardDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.
Mark D AdameDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.ORCID 0000-0002-1345-2941
Nicole R FalkowskiDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.
Roderick A McDonaldDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.
Annastasia PetouhoffDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.
Jennifer M BakerDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.ORCID 0000-0003-1363-1525
Michael McLellanDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States.
Lauren L AragonesDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States.
JaKyla KaniaruDivision of Pulmonary, Critical Care, and Occupational Medicine, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, United States.
Benjamin H SingerDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.ORCID 0000-0002-4721-6920
Robert P DicksonDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan, United States.ORCID 0000-0002-6875-4277
Kathleen A StringerDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States.ORCID 0000-0003-0238-7774
Funding
PULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9M
Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer’s Disease NeuropathologyR01AG074968 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Benjamin Herschel Singer · 2022 to 2026
$3.3M
Translational Metabolomics in Critical CareR35GM136312 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KATHLEEN A STRINGER · 2020 to 2026
$2.8M
The role of the lung microbiome in oxygen-induced lung injuryR01HL144599 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DICKSON, ROBERT PICKETT · 2019 to 2023
$2.1M
Midcareer Investigator Award in Patient-Oriented Research in the Microbiome and Lung DiseaseK24HL159247 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 2022 to 2026
$625k
The Role of the Gut Microbiome in Post-Sepsis Skeletal Muscle AtrophyK08AR083015 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kale S Bongers · 2024 to 2026
$507k
Determining the Injury-Associated Microbial Nutrients that Facilitate Secondary Bacterial Infection in Acutely Injured LungsF31HL158033 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BAKER, JENNIFER MARIE · 2022 to 2024
$120k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) F31HL158033HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) K24HL159247HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL144599HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) T32HL007749HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) K08AR083015HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM136312HHS | NIH | National Institute on Aging (NIA) R01AG074968NHLBI NIH HHS F31 HL158033NHLBI NIH HHS K24 HL159247NHLBI NIH HHS R01 HL144599NHLBI NIH HHS T32 HL007749NIAMS NIH HHS K08 AR083015NIA NIH HHS R01 AG074968NIGMS NIH HHS R35 GM136312
6 · The paper itself
Abstract
Peritonitis is a well-known complication of bowel perforation and abdominal surgery, leading to sepsis and high mortality. Despite its prevalence and severity, the pathogenesis of peritonitis remains incompletely understood, limiting our ability to develop targeted medical therapies. Specifically, little is known about the determinants of the peritoneal nutrient environment for pathogens. The gut microbiome is a well-established source of infectious bacteria in peritonitis, but whether it also modulates levels of nutrients that enable and sustain these infections remains unknown. Using multiple murine models of peritonitis (lipopolysaccharide and cecal slurry), multiple methods of microbiome modulation (germ-free mice and antibiotic-treated mice), novel ex vivo modeling of peritonitis, and nuclear magnetic resonance (NMR) metabolomics of the peritoneal microenvironment, we performed a series of experiments to determine how the gut microbiome influences peritoneal metabolite concentration during peritonitis. We found that both lipopolysaccharide and cecal slurry peritonitis caused consistent changes in high-abundance peritoneal metabolites and that many of these changes were blunted or completely abrogated in antibiotic-treated and germ-free mice. Moreover, we found that peritoneal washings from septic, microbiome-depleted animals supported less bacterial growth of common intra-abdominal pathogens compared with washings from septic conventional animals. We identified the peritoneal nutrients consumed by two common pathogens from the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Gut microbiome-mediated nutrients alter opportunistic bacterial growth in peritonitis. · full record | OpenQuestion